Compare AstraZeneca plc (AZN) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Jones Lang LaSalle Inc — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while Jones Lang LaSalle Inc trades at $315.67 (market cap $14.94B). The key difference: AstraZeneca plc is far larger — about 16.9× Jones Lang LaSalle Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| AZN | JLL | |
|---|---|---|
Market Cap | $253.13B | $14.94B |
Sector | Health | Real Estate |
52-Week High | $209.48 | $358.66 |
52-Week Low | $137.44 | $248.95 |
Enterprise Value | $279.37B | $18.48B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
JLL trades at $321.95, down 0.77% today, with a bullish technical outlook supported by moving averages and strong support near $319. The company shows robust fundamentals with revenue growth to $26.12B in 2025 and consistent earnings beats, while valuation ratios like P/E of 17.32 and P/S of 0.58 appear reasonable. Recent news highlights significant refinancing deals and positive AI workforce studies, reinforcing business momentum.
JLL offers a favorable risk-reward profile with a consensus price target of $405.50 implying 26% upside, backed by analyst optimism and improving cash flows. Key risks include economic sensitivity to real estate cycles and competitive pressures. The stock presents a growth opportunity driven by operational execution and market leadership, though investors should monitor debt levels and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
